About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a company based in Rockville (United States) founded in 2005. The company has 674 employees. Supernus Pharmaceuticals has completed 3 acquisitions, including Adamas Pharma, Biscayne Pharma and SAGE Therapeutics. Supernus Pharmaceuticals offers products and services including QELBREE. Supernus Pharmaceuticals operates in a competitive market with competitors including Alto Neuroscience, Newron Pharmaceuticals, Neurovance, Seaport Therapeutics and Pasithea, among others.
- Headquarter Rockville, United States
- Employees 674
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website supernus.com
- Social LinkedIn
- Legal Name Supernus Pharmaceuticals, Inc.
- Annual Revenue$718.95 M (USD)8.63as on Dec 31, 2025
- Net Profit-$38.55 M (USD)-152.19as on Dec 31, 2025
- EBITDA$54.4 M (USD)-61.63as on Dec 31, 2025
- Latest Funding Round$30M (USD), Post-IPO
Jul 2014
- InvestorsHealthCare Royalty Partners
& 1 more
- Employee Count674
- Investments & AcquisitionsAdamas Pharma
& 2 more
Products & Services of Supernus Pharmaceuticals
Supernus Pharmaceuticals offers a comprehensive portfolio of products and services, including QELBREE.
Approved treatment for central nervous system disorders
Funding Insights of Supernus Pharmaceuticals
- Total Rounds 2
- Last Round Post-IPO — $30M
- First Round $449,754
(Jun 2012)
- Investors Count 2
All 2 funding rounds of Supernus Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2014 | $30M | Post-IPO | – | – | |
| Jun 2012 | $449,754 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Supernus Pharmaceuticals
Supernus Pharmaceuticals has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HealthCare Royalty Partners and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare royalty investments are focused on US and UK markets. | – | healthcareroyalty.com | Stamford, United States | |
- | – | hhs.gov | - |
Investor details for Supernus Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Supernus Pharmaceuticals
301 people are tracked at Supernus Pharmaceuticals (94 in leadership, 7 in board & advisors, 200 in team); the tracked headcount is 674.
| Name | Role | Group |
|---|---|---|
Jack Khattar | CEO & President | Leadership |
Jack A. Khattar | President & CEO | Leadership |
Rose Lieberman | Associate Director, Clinical Development | Leadership |
Sarah Torres | Director, Marketing | Leadership |
Henry Anderson | Director, Digital Marketing & Omnichannel Operations | Leadership |
Steve Gabuzda | Regional Director - Great Lakes | Leadership |
Sarah Branning | Associate Director, Access Reimbursement Management | Leadership |
Tiffany Caçoilo | Director, Human Resources- HR Partners | Leadership |
Uzma Zafer | Senior Executive Assistant To Senior Vice President | Leadership |
Grace Jan | Director, Sales Operations And Corporate Events | Leadership |
Rigo C. | Vice President Of Commercial Operations | Leadership |
MacIej Gasior | Executive Director, Clinical Development | Leadership |
Jonathan Rubin | Chief Medical Officer & SVP, Research & Development | Leadership |
Gang Luo | Director, Preclinical DMPK & Pharmacology | Leadership |
Austin Eikenberry | Associate Director | Leadership |
Padmanabh P. Bhatt | SVP, Intellectual Property and Chief Scientific Officer | Leadership |
Ernane Souza | Associate Director, Translational PKPD And DMPK | Leadership |
Kisha Bethune | Senior Director Sales Effectiveness & Analytics | Leadership |
Sesilie Oehler | National Account Director- Commercial & Govt; National Sales Director - Federal Accounts | Leadership |
Chris March | Vice President Human Resources | Leadership |
281 more people are available in the full profile.
Complete people profiles for Supernus Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Supernus Pharmaceuticals
Supernus Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol SUPN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 May 2012
- Listed onNASDAQ: SUPN
- Listed entitySupernus Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS8684591089
- Share price$42.67 (+1.26% on the day) · 2026-10-09
- Market capitalisation$2.48B
- EPS (diluted, trailing year)$-1.91
- Volume (last session)643,833
Financials of Supernus Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $719.0M | -$38.5M | $54.4M |
| 2024 | $661.8M | $73.9M | $141.8M |
| 2023 | $607.5M | $1.3M | $98.3M |
| 2022 | $667.2M | $60.7M | $131.2M |
| 2021 | $579.8M | $53.4M | $133.8M |
Detailed financial statements for Supernus Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Supernus Pharmaceuticals
Supernus Pharmaceuticals has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Adamas Pharma, Biscayne Pharma and SAGE Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of drug candidates for the treatment of rare CNS disorders | sagerx.com | Boston, United States | 1971 | Jun 2025 | $795M | |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics. | adamaspharma.com | Emeryville, United States | 2002 | Oct 2021 | $400M | |
Clinical-stage drugs for CNS disorders and drug-resistant cancers are developed. | biscaynepharma.com | Miami, United States | 2012 | Sep 2018 | $185M |
Complete acquisition details for Supernus Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Supernus Pharmaceuticals
7 dated milestones of Supernus Pharmaceuticals across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Supernus Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $450K.
- Funding Latest funding round, Post-IPO, of $30.0M.
- Acquisition Acquires Biscayne Pharma.
- Acquisition Acquires Adamas Pharma.
- Acquisition Acquires SAGE Therapeutics.
Competitors of Supernus Pharmaceuticals
Supernus Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Newron Pharmaceuticals, Neurovance, Seaport Therapeutics and Pasithea, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| newron.com | 1999 | Milan, Italy | $54.94M | – | Therapies for central nervous system diseases and pain are developed. | |
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. | |
| seaporttx.com | 2020 | Boston, United States | $325M | – | Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology. | |
| pasithea.com | 2020 | Miami Beach, United States | $1.46M | 15 | Pasithea is focused on developing treatments for neurological disorders. | |
| synchroneuron.com | 2006 | Newton, United States | $26M | – | Improved acamprosate formulations are developed for neuropsychiatric disorders. | |
| naurex.com | 2008 | Evanston, United States | $162.11M | – | Novel therapies for depression and CNS disorders are developed clinically. | |
| cadenttx.com | 2010 | Cambridge, United States | $63.73M | 13 | Precision medicines for neurological diseases are developed by Cadent Therapeutics. | |
| reunionneuro.com | 2022 | Toronto, Canada | $103M | – | Therapeutics for mental health conditions are developed using serotonergic psychedelics. |
Detailed competitors of Supernus Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Supernus Pharmaceuticals
The website of Supernus Pharmaceuticals (supernus.com) receives about 18.7K visits a month and ranks #1,928,683 among all websites worldwide, #2,630 in Biotechnology and Pharmaceuticals.
- Monthly visits18.7K
▲ 47% vs previous month
- Unique visitors6.8K
per month
- Global rank#1,928,683
among all websites
- Category rank#2,630
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit1.6
- Average visit25 sec
- DevicesDesktop 39% · Mobile 61%
Websites whose visitors overlap most with Supernus Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sucampo.com | 100% | – | – | View details | |
| alkermes.com | 92% | 22.7K | #1,117,011 | View details | |
| astx.com | 92% | 8.9K | #2,592,392 | View details | |
| dermavant.com | 86% | – | – | View details | |
| takeda.com | 84% | 620.1K | #93,966 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Supernus Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Supernus Pharmaceuticals
Complete news archive for Supernus Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Supernus Pharmaceuticals
10 companies that operate in the same segment as Supernus Pharmaceuticals (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Supernus Pharmaceuticals
Supernus Pharmaceuticals was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Supernus Pharmaceuticals is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Jack Khattar is the current CEO of Supernus Pharmaceuticals.
Supernus Pharmaceuticals has 674 employees.
Annual revenue of Supernus Pharmaceuticals is $718.95M as on Dec 31, 2025.
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, United States. Operations center on the development and commercialization of treatments for central nervous system diseases. Key products, such as Oxtellar and Trokendi, address epilepsy. The psychiatry pipeline features SPN-810 for impulsive aggression, SPN-812 for ADHD, and SPN-809 for depression. An acquisition of its parent company, Shrine Labs, occurred in late 2005.
Supernus Pharmaceuticals's top competitors include Alto Neuroscience, Newron Pharmaceuticals and Seaport Therapeutics.
Supernus Pharmaceuticals offers QELBREE.
Yes, Supernus Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol SUPN.
Supernus Pharmaceuticals has made 3 acquisitions, including Adamas Pharma, Biscayne Pharma, and SAGE Therapeutics.
Supernus Pharmaceuticals has 2 investors. Key investors include HealthCare Royalty Partners, and HHS.
Supernus Pharmaceuticals operates through Supernus Pharmaceuticals, Inc..